Document:

Contract Research Agreement, dated December 14, 2001

 Exhibit 10.20 
  
 CONTRACT RESEARCH AGREEMENT 
  

CDT INTERNATIONAL LIMITED (1) 
  
 AND 
  
 COVION ORGANIC SEMICONDUCTORS GMBH (2) 
  
 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH OMISSIONS ARE NOTED BY “[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT
HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION. 

 CONTRACT RESEARCH AGREEMENT 
  
 THIS AGREEMENT is made the 14 day of December 2001 between: 
  

	(1)	CDT INTERNATIONAL LIMITED, a company incorporated in Bermuda whose registered office is situated at PO Box HM1556, Corner House Church, Parliament Street, Hamilton HMFX,
Bermuda (“CDT”); and 

  

	(2)	COVION ORGANIC SEMICONDUCTORS GMBH, a company incorporated in Germany whose principal place of business is situated at Industriepark Hoechst, Gebaude G864, D-65926, Frankfurt
am Main, Germany (“Covion”). 

  
 RECITALS:

  

	(A)	CDT has, and/or has an Affiliate which has, scientists skilled in the art of the design and development of organic semiconductors and CDT is prepared to carry out, and/or procure
that such Affiliate carries out, research and development into this area on behalf of Covion. 

  

	(B)	Covion has considerable experience and valuable technical and commercial information and know-how in the field of organic semiconductors and wishes CDT to carry out, and/or procure
the carrying out by such Affiliate of CDT of, contract research and development on behalf of Covion. 

  

	(C)	The Parties therefore wish to enter into this Agreement to specify as between CDT and Covion the terms and conditions of the working relationship between CDT and/or CDT’s
Affiliate and Covion in relation to the design and development of organic semiconductors. 

  
 IT IS HEREBY AGREED AS FOLLOWS: 
  

	1.	DEFINITIONS 

  

	1.1	In this Agreement including its Schedules, the headings are included for ease of reference only and shall not affect its interpretation and the following terms shall have the
following meanings unless the context otherwise requires: 

  
 “Affiliate” means, at the relevant time, any business entity which controls, is controlled by or is under common control with the business entity referred to but in each case only for so long as such
control or common control relationship exists; for the purposes of this definition a business entity shall be deemed to “control” another business entity if it owns, directly or indirectly, in excess of 50% of the outstanding voting
securities or capital stock of such business entity or any other comparable equity or ownership interest with respect to a business entity other than a corporation. 
  

 2 

 “Assigned Patent” means patent application WO 00/55927 (together with the rights to all
Patents claiming priority therefrom including associated or national regional patents and continuations thereof). 
  
 “Avecia Group Company” means Avecia Limited (a company incorporated in England with company number 3730853) or any Affiliate of Avecia.

  
 “Calendar Quarter” means the period from the
Effective Date to 31st March 2002 and thereafter each successive period of three (3) months ending on, 30th June,
30th September, 31st December and 31st March. 
  
 “CDT Group Company” means CDT or any Affiliate of CDT. 
  
 “CDT Limited” means Cambridge Display Technology Limited (a company incorporated in England with company
number 2672530). 
  
 “Confidential Information”
means all confidential information disclosed by one party or any of its Affiliates (“the Disclosing Party”) to the other party or any of its Affiliates, (“the Receiving Party”) pursuant to this Agreement in written
verbal or any other form, including, without limitation, data, know-how, formulae, compositions, designs, photographs, drawings, specifications, software program, samples, any product made using the samples and any other material bearing or
incorporating any information relating to such information. 
  
 “Covion Group Company” means Covion or any Affiliate of Covion. 
  
 “Covion Licensee” means any Covion Group Company, any Avecia Group Company, any Relevant Joint Venture of any Covion Group Company and/or any Relevant Joint Venture of any Avecia Group Company;

  
 “Covion OLEM Products” means conjugated
Polymeric OLEMs (other than PLEMs) or formulations containing conjugated polymeric OLEMs (other than PLEMs) sold pursuant to a supply agreement for use in the Field. 
  
 “Covion OSC Products” means organic semiconductors or formulations containing organic semiconductors sold
pursuant to a supply agreement for use outside the Field where the sale or any other aspect of the exploitation of such organic semiconductors or formulations containing organic semiconductors by Covion or any Covion Licensee or by a direct customer
of Covion or any Covion Licensee has taken place in a country in which such sale or other aspect of the exploitation falls within any of the then still valid claims licensed to Covion under a patent covering that country in accordance with the
Patent and Know-How Licence or falls within any of: 
  

	 	(a)	the then still valid claims in a patent covering that country owned by Covion for an invention covered by Clause 7.5 of this Agreement; or 

  

 3 

	 	(b)	the know-how owned by Covion for an invention which is considered to be equivalent to a patent in that country pursuant to clause 7.5 of this Agreement. 

  
 “Covion Products” means Covion OLEM Products and/or Covion
OSC Products. 
  
 “Device Facilities” means CDT
Limited’s physics and Device facilities in Cambridge. 
  
 “Devices” means devices containing organic semiconductors. 
  
 [**] 
  
 “Effective
Date” means the date of this Agreement. 
  
 “Existing Patents” means the patents and/or patent applications owned or to be owned by any CDT Group Company or to which any CDT Group Company has/will have relevant rights which enable such CDT Group Company to
license/sub-license third parties and which in either case are for inventions, made prior to the Effective Date which were not made or otherwise acquired pursuant to or as part of a pre-existing relevant business by a CDT Group Company at any time
before it became an Affiliate of CDT. 
  
 “exploitation” means manufacture, import, keeping, use and/or sale (including in relation to any such activity offering to do any of these). 
  
 “Field” means the field of displays and lighting. 
  
 “Intellectual Property Rights” means patents, designs,
design rights, copyright, right in know-how and other intellectual property rights, in each case whether registered or unregistered and including applications for the grant of any of the foregoing and all rights or forms of protection having
equivalent or similar effect to any of the foregoing which may subsist anywhere in the world. 
  
 “Materials Evaluation Agreement” means the agreement to be entered into between CDT Limited and Covion in the form set out in Schedule 1 to this Agreement contemporaneously with this Agreement.

  

 4 

 “Net Sales Value” means the gross invoice price for sales on an arm’s length basis
of Covion Products by Covion or any Covion Licensee to any third party (i.e. an entity other than Covion or a Covion Licensee), less 
  

	 	(i)	the cost of packaging (not forming part of the Covion Products), transportation and insurance; 

  

	 	(ii)	commissions, early payment discounts (but only where these are in accordance with local business custom and practice), trade discounts or quantity discounts actually granted;

  

	 	(iii)	allowances or credits actually granted to customers on account of settlement of complaints, returns and replacements; and 

  

	 	(iv)	sales taxes and/or other taxes and/or tariff duties directly imposed on sales of Covion Products. 

  
 Where Covion Products are sold other than on an arm’s length basis to a third party (i.e. an entity other than Covion
or a Covion Licensee), the Net Sales Value shall be deemed to be the average gross invoice price obtained by Covion or the relevant Covion Licensee (as the case may be) for sales on an arm’s length basis over the six months immediately
preceding the transaction in question less those items specified above. 
  
 “OLEMs” means organic light-emitting materials. 
  
 “Patent and Know-How Licence” means the patent and know-how licence of even date herewith between CDT Limited and Covion. 
  
 “PLEMs” means (a) Polyfluorenes; (b) solid compositions
containing Polyfluorenes in an amount of at least one percent (1%) by weight; and (c) solutions containing “Polyfluorenes” including formulations for ink jet printing; for the purposes of this definition “Polyfluorenes”
means any polymer having substituted or unsubstituted 2,7-linked fluorene mer units but does not include polymer where all the fluorene units are spirofluorenes or indenofluorenes. 
  
 “Project” means a research and development programme concerning the use of OLEMs in the Field designated by
Covion pursuant to this Agreement. 
  
 “Relevant CDT
Group Company” means CDT and/or any relevant Affiliate of CDT engaged by CDT pursuant to clause 2.1. 
  
 “Relevant Joint Venture” means any joint venture in which the business entity referred to has at least a 50% interest in the outstanding
voting securities or capital stock of such joint venture or any other comparable equity or ownership interest with respect to a business entity other than a corporation. 
  

 5 

 “Results” means all information, results, inventions, improvements, discoveries,
hypotheses, developments, scientific knowledge and know-how conceived as a direct consequence of work conducted pursuant to any Project under this Agreement or using the Confidential Information of Covion provided under this Agreement whether
conceived solely by any CDT Group Company personnel or Covion personnel or jointly by any CDT Group Company personnel and Covion. 
  
 “Royalty Income” means any income (after deduction of any taxes imposed directly on such income) from sales of organic semiconductors
obtained by Covion or any Covion Licensee from the licensing to any third party (i.e. an entity which is not a Covion Licensee) of any patent owned at any time by Covion for an invention covered by Clause 7.5 of this Agreement or any know-how owned
at any time by Covion for an invention which is considered to be equivalent to a patent in certain countries pursuant to Clause 7.5 of this Agreement. 
  
 “Third Party Patent” means any patent or patent application belonging to a party unconnected with any party to this Agreement with a
priority date on or prior to the Effective Date. 
  

	1.2	A reference to any party to this Agreement shall include a reference to its legal successors and permitted assignees. 

  

	1.3	References to recitals, clauses, paragraphs, and schedules, are to recitals, clauses paragraphs and schedules to this Agreement. 

  

	1.4	The Schedules form part of this Agreement and shall have the same force and effect as if expressly set out in the body of the Agreement and any reference to the Agreement shall
include the Schedules. 

  

	1.5	References to writing shall include any mode of reproducing words in a legible and non-transitory form. 

  

	1.6	References to “£” and “pounds sterling” are references to the currency of the United Kingdom. 

  

	2.	SPECIFICATION AND PERFORMANCE OF PROJECTS 

  

	2.1	CDT shall provide (or shall procure the provision by a CDT Affiliate of) the full time effort of at least ten graduate scientists skilled in the art of the design and development of
organic semiconductors (of whom a minimum of five must be educated to phD level) to carry out Projects pursuant to this Agreement and 

  

 6 

 sufficient time of a skilled project manager to oversee this work within the Relevant CDT Group Company
(“CDT Project Manager”). CDT shall ensure that any scientists involved in any Project will not work on projects within any CDT Group Company to develop organic semiconductors for third parties or on any independent projects to
develop organic semiconductors within any CDT Group Company. 
  

	2.2	Covion shall also appoint a skilled project manager to work with the CDT Project Manager in directing the Projects (“Covion Project Manager”). The Covion Project
shall designate the scope, the targets and the associated work programmes for each Project in consultation with the CDT Project Manager. The CDT Project Manager will provide a written monthly report to the Covion Project Manager on the progress and
direction of each Project and they will otherwise meet as necessary in order to assess the Progress and direction of each Project. 

  

	2.3	The actual work under each Project may be carried out solely by the Relevant CDT Group Company or by the Relevant CDT Group Company in collaboration with personnel of Covion. The
CDT Project Manager shall oversee any work done on a Project by Covion personnel at the Relevant CDT Group Company’s premises unless otherwise agreed with the Covion Project Manager. 

  

	2.4	CDT: 

  

	 	(a)	warrants that the Relevant CDT Group Company has the expertise and resources to perform research and development in the area of organic semiconductors; and 

 

	 	(b)	shall, or shall procure that the Relevant CDT Company shall, carry out the research and development under each Project with the care and skill reasonably to be expected of chemists
skilled in the art of the design and development of organic semiconductors but Covion acknowledges that no CDT Group Company gives any representation or warranty that any such work as is carried out pursuant to a Project will be successful in
achieving the objective of such Project. 

  

	2.5	All costs incurred by Covion pursuant to any project shall be borne by Covion. All costs incurred by the Relevant CDT Group Company pursuant to any Project shall (as between CDT and
Covion) be borne by CDT. Covion and the Relevant CDT Group Company shall each provide all necessary infrastructure and support to its staff up working on any Project (including in the case of Covion travel, lodging, meals and other living and
incidental expenses for such Covion personnel involved on any Project and the Covion Project Manager). The Relevant CDT Company shall make available such equipment and Support capacities as would reasonably be required to support a synthetic
chemistry 

  

 7 

 activity involving ten scientists and of a quality consistent with a state of the art industrial chemical
research organisation. Covion and the relevant CDT Group Company shall each fund its own efforts for carrying out each Project including, without limitation, funding manpower and capital resources. However no CDT Group Company can be required to
commit to external purchases of specialized monomers at a level that would be equivalent to commercial manufacturing scale (which for these purposes shall mean manufacture of one half of one kilogramme or more of an organic semiconductor).

  

	2.6	The research and development on each Project shall be carried out at CDT Limited’s Cambridge research and development facilities at the relevant time. The laboratories in which
the Projects will be carried out will comply with all UK COSHH requirements. The personnel of Covion involved in any Project and the Covion Project Manager shall be allowed access to such laboratories (subject to any normal security requirements)
and (subject to CDT Limited’s requirements and commitments in respect thereof) to use any relevant equipment during normal business hours in the same way as the Relevant CDT Group Company’s personnel working on such Project.

  

	2.7	CDT shall ensure that the Relevant CDT Group Company’s personnel and any Covion staff working on any Project shall, on reasonable notice and subject to CDT Limited’s
requirements and commitments in respect thereof, have such access free of charge as may be necessary in connection with any such Project to the Device Facilities solely for the purposes of research, development and testing in relation to OLEMs in
the Field. Covion staff shall also be entitled to make use of the Device Facilities free of charge solely for research and development in relation to organic semiconductors being carried out by Covion other than pursuant to or in connection with
ally projects during normal business hours on reasonable notice subject to CDT Limited’s requirements and commitments in respect thereof. 

  

	2.8	Any Project may be varied by the Covion Project Manager from time to time in consultation with the Relevant CDT Group Company so as to give the best opportunity to deliver the
objectives of such project. Each project shall be conducted by the Relevant CDT Group Company within overall parameters as agreed with Covion. 

  

	2.9	After completion of each stage of any Project, Covion and the Relevant CDT Group Company shall each in a timely manner communicate to the other in writing the Results.

  

	2.10	Representatives from Covion and the Relevant CDT Group Company involved in each Project shall meet at such times and in such places as the respective project managers shall agree in
order to discuss the progress of the Project, any issues arising and agree any modifications to the objective of the Project. 

  

 8 

	2.11	For the avoidance of doubt, any time periods specified for the carrying out of any Project shall be indicative only. 

  

	2.12	For the avoidance of doubt, it shall not be considered a breach of this Agreement by either Party (or any other Relevant CDT Group Company) if the objectives of any Project are not
achieved so long as Covion and the Relevant CDT Group Company each uses reasonable technical endeavours in the performance of its obligations. 

  

	2.13	Each party (and any other Relevant CDT Group Company) will at all times act in the utmost good faith towards the other party in connection with this Agreement and the research to be
carried out under it pursuant to any Project. Each party (and any other Relevant CDT Group Company) shall, in commissioning and carrying out individual Projects, act in accordance with good industrial and scientific practice.

  

	3.	LICENCE/RIGHTS TO COVION PATENTS AND KNOW-HOW 

  

	3.1	Covion hereby grants to the Relevant CDT Group Company solely for the benefit of those of its personnel working on any Project a non-exclusive licence under any patents and know-how
owned by Covion (or licensed to it) from time to time solely to allow such personnel to carry out research and development on Projects pursuant to this Agreement. 

  

	3.2	Covion shall in a timely manner provide in written or oral form (as the parties may agree) such know-how of or licensed to Covion in the field of organic semiconductors as Covion
considers those personnel of the Relevant CDT Group Company working on any Project may reasonably require to carry out research and development pursuant to any Project (subject to the confidentiality provisions referred to in paragraph 9 below).

  

	4.	CONSIDERATION 

  

	4.1	Covion shall, in respect of CDT’s agreement to provide (or procure the provision of): 

  

	 	4.1.1	the research and development work carried out by the Relevant CDT Group Company pursuant to this Agreement; 

  

 9 

	 	4.1.2	access to and use of the equipment of the Relevant CDT Group Company being used in any project in the research and development of organic semiconductors; and

  

	 	4.1.3	access to and use of the Device Facilities, 

  
 pay to CDT a royalty (excluding VAT or other sales tax if applicable) of [**] of the Net Sales Value of all Covion Products sold during the term of this
Agreement. 
  

	4.2	For the avoidance of doubt no royalties shall be payable on sales of Covion Products by Covion or any Covion Licensee to any CDT Group Company or any other company in which CDT owns
at least 25% of the equity share capital. Also for the avoidance of doubt royalties on any Covion Products manufactured by any toll manufacturer shall be payable on the subsequent sale of those products by Covion or any Covion Licensee and not on
the original sale by the toll manufacturer to them. 

  

	4.3	No royalties shall be due to CDT in respect of any Covion Products used by Covion or any Covion Licensee for the further development of Covion Products by Covion or any Covion
Licensee or for quality control procedures in the manufacture or sale of Covion Products or disposed of free of charge for the purposes of promoting the sale of Covion Products. 

  

	4.4	In this Agreement the expression “sold” or any cognate expression shall be deemed to include any type of supply for value. 

  

	4.5	Covion shall, in respect of CDT’s agreement to provide (or procure the provision of): 

  

	 	4.5.1	the research and development work carried out by the Relevant CDT Group Company pursuant to this Agreement; 

  

	 	4.5.2	access to and use of the equipment of the Relevant CDT Group Company being used in any project in the research and development of organic semiconductors; and

  

	 	4.5.3	access to and use of the Device Facilities, 

  
 also pay to CDT a royalty (excluding VAT or other sales tax if applicable) of [**] of the Royalty Income obtained by Covion or any Covion Licensee during
the term of this Agreement. 
  

	4.6	[**] 

  

 10 

	5.	ACCOUNTING AND PAYMENT 

  

	5.1	Royalties shall be payable yearly in arrears sixty (60) days after the end of the last day of each calendar year during the term of this Agreement with the last such payment to be
made within (60) days after the end of the last day of the calendar year during which this Agreement expires or terminates. 

  

	5.2	Covion shall, and shall Procure that any Covion Licensee shall keep at its usual place of business records of account sufficient to enable accurate calculations of royalties due to
CDT and shall produce and present to CDT a statement of those royalties no later than sixty (60) days after the end of each calendar year during the term of this Agreement. If there is a dispute between the parties about the amount of royalties
payable, the Parties shall select an independent accountant to be agreed between them, or in default of agreement to be appointed by the President for the time being of the Institute of Chartered Accountants in England and Wales, to inspect the
records of Covion and/or any Covion Licensee on reasonable notice and during normal business hours to verify Covion’s statements and royalty payments due pursuant to this Agreement. If such inspection reveals that any statement or payment shall
not have been rendered or made in accordance with the terms of this Agreement, or that any statement rendered or payment made by Covion was inaccurate by more than five per cent (5%) then Covion shall pay the cost of such inspection without
prejudice to any other remedies or claims of CDT. Such accountant shall not disclose to CDT any information other than information relating to royalties owed by Covion pursuant to this Agreement. CDT shall maintain in confidence and shall oblige the
independent accountant to maintain in confidence all information received pursuant to this subclause. The decision of the independent accountant as to the amount of royalty Payment to be made shall, in the absence of manifest error, be final and
binding upon the parties. 

  

	5.3	All royalties shall be calculated in the currency in which Covion keeps its accounts and shall be paid to CDT in euros in London to the credit of a bank 

  

 11 

 account to be designated in writing by CDT the rate of conversion being the relevant buying rate of HSBC
Bank plc at close of business on the last business day of the before the day payment is due. 
  

	5.4	All sums shall be paid in full without deductions or set-off, except only for such taxes, or other levies or duties as Covion is legally bound to withhold. Covion shall assist CDT
without charge to recover (under the provisions of double tax conventions or other lawful manner) any tax so withheld. If VAT is payable on any of the royalties then Covion shall pay VAT pursuant to a VAT invoice to be submitted by CDT.

  

	6.	CONFIDENTIALITY 

  

	6.1	All Results shall be deemed to be the Confidential Information of Covion. 

  

	6.2	Without the prior written consent of the other party (which shall not be unreasonably withheld or delayed), neither party (nor any of its Affiliates) shall disclose to any third
party the existence of this Agreement, any part of the contents or terms and conditions of this Agreement, that any Project is taking place or has taken place or the status thereof at any time or any other facts in respect of this Agreement or any
Project. 

  

	6.3	In consideration of the Disclosing Party disclosing or otherwise making available any Confidential Information to the Receiving Party, the Receiving Party hereby undertakes:

  

	 	6.3.1	not to use the Confidential Information of the Disclosing Party for any purpose other than for the purpose of a Project pursuant to this Agreement (“the Purpose”);

  

	 	6.3.2	where the Receiving party is any CDT Group Company, to ensure that the CDT Project Manager and any CDT scientists Involved in any Project shall not disclose any Confidential
Information of Covion (including Results) to any other director, employee and/or other personnel of any CDT Group Company; 

  

	 	6.3.3	to maintain the confidentiality of the Confidential Information and not to disclose it directly or indirectly to any third party, whether an affiliated company, organisation,
individual or otherwise, save as permitted by Clauses 6.4 and 6.5; and 

  

	 	6.3.4	to take reasonable and appropriate measures to secure the confidentiality attaching to the Confidential Information of the Disclosing Party and safeguard it against theft, loss or
negligent disclosure to others, including but not limited to the same measures as the Receiving Party takes to protect its own confidential information. 

  

 12 

	6.4	Covion may solely for the purposes of the Projects contemplated by this Agreement disclose Confidential Information of any CDT Group Company to: 

  

	 	6.4.1	any of its Affiliates provided that Covion shall procure that prior to such disclosure each Affiliate to which Confidential Information is to be disclosed is made aware of the
obligations contained in this Agreement and agrees to be subject to confidentiality obligations no less onerous than those contained in this Agreement; any breaches of the obligations of confidentiality contained in this Agreement by such Affiliates
shall be treated as a breach of such obligations by Covion; and 

  

	 	6.4.2	its directors and employees and/or other personnel (and to the directors and employees and/or other personnel of the Affiliates to whom disclosure may be in accordance with Clause
6.4.1) who need to know the Confidential Information in order to fulfil the Purpose, provided that Covion shall procure that prior to such disclosure each of those directors and employees and/or other personnel to whom Confidential Information is to
be disclosed is made aware of the obligations of confidentiality and non-use herein contained and any breaches of the obligations of confidentiality contained in this Agreement by such directors and employees and/or other personnel (and directors
and employees and/or other Personnel of such Affiliates) shall be treated as a breach of such obligations by Covion. 

  
 Any reference to the Receiving party in Clause 6.6 where such Receiving Party is Covion shall be deemed to include reference to its Affiliates to whom
Confidential Information of any CDT Group Company has been disclosed pursuant to this Clause 6.4. 
  

	6.5	Nothing in this Clause 6 shall preclude disclosure of any Confidential Information required by any court entitled by law to disclosure of the same, or which is required by law to be
disclosed, provided that the Receiving Party promptly notifies the Disclosing Party when such requirement to disclose has arisen, to enable the Disclosing Party to seek an appropriate protective order and to make known to the said court the
proprietary nature of the Confidential Information and to make any applicable claim of confidentiality in respect thereof. The Receiving Party agrees to co-operate in any appropriate action which the Disclosing Party may decide to take. If the
Receiving Party is required to make a disclosure it shall only make a disclosure to the extent to which it is obliged. The parties agree that any submission or presentation to any competition law authority in relation to this Agreement shall be made
jointly, but nothing in this Clause 6 shall preclude the 

  

 13 

 making of an appropriate submission or presentation to any competition law authority in response to a
legal requirement imposed by a competition law authority provided that the party in receipt of such a requirement promptly notifies the other party and consults with the other party as to the content of such submission or presentation. 

 

	6.6	The provisions of this Clause 6 shall not apply to any information comprising Confidential Information which the Receiving Party can demonstrate to the reasonable satisfaction of
the Disclosing Party: 

  

	 	6.6.1	was already in the possession of the Receiving Party and at the Receiving Party’s free use and disposal or in the public domain prior to its disclosure by the Disclosing Party
hereunder; or 

  

	 	6.6.2	is legally acquired by the Receiving Party at any time from a third party having good title thereto and the unrestricted right to disclose the same; or 

  

	 	6.6.3	comes into the public domain, otherwise than through the fault of the Receiving Party; or 

  

	 	6.6.4	is independently generated by the Receiving Party without any recourse or reference to any Confidential Information disclosed by the Disclosing Party. 

  

	6.7	The obligations of the Receiving Party set out in this Clause 6 shall in respect of the Confidential Information of the Disclosing Party survive for a period of five years from the
termination of this Agreement. 

  

	7.	RESULTS AND INTELLECTUAL PROPERTY RIGHTS 

  

	7.1	Nothing in this Agreement shall affect the ownership by either party of any inventions, improvements, developments, discoveries, processes, methods, scientific knowledge, know-how
and/or other technical information discovered, created or conceived by that party (or any of its Affiliates) or to which that party (or any of its Affiliates) has the necessary rights on or prior to the Effective Date. For the avoidance of doubt,
any inventions, improvements, developments, discoveries, processes, methods, scientific knowledge, know-how and other technical information conceived by either party (or any of its Affiliates) outside of any work conducted pursuant to a Project
under this Agreement and without using the Confidential Information of the other party (or any of its Affiliates) provided under this Agreement shall be owned by the party (or its Affiliate) which discovers, creates or conceives it.

  

 14 

	7.2	Covion acknowledges that CDT Group Companies will receive organic semiconductors from third parties for testing and development of Devices but CDT shall undertake to ensure that
such organic semiconductors are only available to those staff of any CDT Group Company who are working on the testing and development of Devices and are not made available to those staff of the Relevant CDT Group Company working on any Project or to
those staff of any CDT Group Company who have had access to any Confidential Information of Covion disclosed pursuant to this Agreement so as to ensure that CDT can ensure that each CDT Group Company complies with the provisions of the remainder of
this Clause 7. 

  

	7.3	All Results shall, irrespective of whether they were discovered, created or conceived solely by either party or jointly by both parties, be solely owned by Covion and each party
will provide or do at Covion’s expense all things, including the execution of all papers by its personnel and the executing of assignments where necessary, in order to ensure that all Intellectual Property Rights in the Results are vested in
Covion. 

  

	7.4	Covion shall have the right to file patent applications in its own name for any invention contained in the Results and to be registered as sole proprietor of all patents resulting
therefrom. Covion shall bear the costs relating to the obtaining and maintaining of any such patents itself. For the avoidance of doubt Covion shall also have the right to obtain any other registered Intellectual Property Rights in its own name for
any invention contained in the Results and to be registered as sole proprietor thereof, Covion shall bear the costs relating to the obtaining and maintaining of any other registered Intellectual Property Rights. 

  

	7.5	Where any invention contained in the Results is technically capable of being patented and has as an inventor a person whose salary was actually paid by CDT at the time of such
invention, then Covion shall be obliged to file a patent application in respect of such invention promptly and judiciously in accordance with good industrial and scientific practice. Covion shall be obliged to file such patent applications in at
least the USA, Japan, Germany and the UK. However if the invention is a patentable process for the manufacture of an organic semiconductor Covion shall be entitled to decide to keep such invention secret rather than patent it but shall for the
purposes of the Patent and Know-How Licence and this Agreement be treated as if such invention had been patented in the USA, Japan, Germany and the UK (Covion shall promptly notify CDT in writing of any decision in this regard). In deciding whether
to patent an invention contained in the Results, in obtaining and maintaining such patent and/or in deciding whether or not to commercialise Covion Products using any such invention Covion shall act equitably towards CDT and in accordance with good
industrial and scientific practice. 

  

 15 

	7.6	If any dispute arises between the parties as to whether any invention referred to in Clause 7.5 is technically capable of being patented shall be referred initially to the patent
attorneys of CDT and Covion for consideration. Failing resolution within 21 days of such referral, the dispute shall be referred for final settlement to an expert nominated jointly by the parties (or failing such nomination within 14 days after a
party’s request thereof) nominated at the request of any party by the President of the Chartered Institute of Patent Agents. Such expert shall be deemed to act as an expert and not as an arbitrator, his decision shall (in the absence of
clerical or manifest error) be formal and binding on the parties and his fees shall be borne equally by the parties unless he determines that the conduct of either party is such that such party should bear all or a higher share of the fees.

  

	7.7	Covion hereby grants to CDT a royalty-free, sole, irrevocable, fully transferable, world-wide licence (with the right to sub-license others) under any claims that relate to or
concern the design, development or fabrication of Devices arising out of the patents filed pursuant to Clause 7.5, such licence to allow CDT to exploit in any manner such Device claims. However such licence shall be limited in that wherever Covion
is obliged by its material evaluation agreements with unconnected third parties to grant rights to third parties in relation to such Device claims, CDT’s licence shall either be non-exclusive or no licence shall be granted (as the case may be)
so as to be compatible with Covion’s obligations to those third parties. Covion shall on a timely basis notify CDT of the existence of any such agreements in relation to any particular Project. For the avoidance of doubt the claims to Devices
referred to in this Clause 7.7 shall not include any claim where such claim (as finally granted) is to an already known (at the date the relevant Patent application is filed) Device comprising a new organic semiconductor or new formulation
containing an organic semiconductor (i.e. where the only inventive part of the claim is the presence of the new organic semiconductor or new formulation containing an organic semiconductor). 

  

	7.8	If Covion assigns or otherwise transfers or disposes of any interest in any Intellectual Property Rights comprised in or relating to any Results to any third party Covion shall, as
a condition of such assignment, transfer or disposal, procure that such third party is bound by the provisions of this Clause 7 as if it is Covion. 

  

	8.	USE OF RESULTS 

  
 Covion shall be exclusively responsible for all Covion Products manufactured sold, used or supplied by Covion or any Covion Licensee and accordingly Covion shall indemnify and keep indemnified the Relevant CDT Group
Company in respect of all costs damages and expenses incurred as a result of any claims by third parties in tort or howsoever otherwise including, without limitation, any relevant legislation or regulation against the Relevant CDT Group Company
arising in any way out of the use of any of the Results as contemplated by or for Covion or by or for any Covion Licensee. 
  

 16 

	9.	MATERIALS EVALUATION AGREEMENT 

  

	9.1	The Relevant CDT Group Company shall Procure that the organic semiconductors arising out of or developed pursuant to any project shall not be provided to any staff of any CDT Group
Company (other than those working on projects pursuant to this Agreement) without the prior written consent of Covion. 

  

	9.2	Covion hereby undertakes at CDT’s request that it will make available to Limited’s staff involved in the development of Devices, free of charge, limited quantities (up to
a maximum of 5g per organic semiconductor) of all organic semiconductors which have been sampled by Covion to other external customers for evaluation in Devices provided CDT Limited has entered into the Materials Evaluation Agreement.

  

	9.3	In respect of organic semiconductors developed by the Relevant CDT Group Company’s staff working on a Project, any such organic semiconductor which it is agreed should be
provided to CDT Limited’s staff involved in the development of Devices in a meeting (including, without limitation, a video-conference or teleconference meeting) between the CDT Project Manager and the Covion Project Manager (as evidenced by
agreed minutes) shall be made available by Covion, free of charge; in limited quantities (up to a maximum of 5g per organic semiconductor) provided CDT Limited has entered into the Materials Evaluation Agreement. The Covion Project Manager shall not
unreasonably withhold or delay his consent to the release of such samples to CDT Limited’s staff involved in the development of Devices. 

  

	9.4	It is the intention of the parties in due course to discuss and seek to agree on a case-by-case basis the provision (and the terms of such provision) of larger quantities of organic
semiconductors (for which CDT acknowledges on behalf of CDT Limited that Covion would require payment) to CDT Limited for the purposes of general Devices research. It is also the intention of the parties to discuss and seek to agree separate
agreements to enable CDT Limited to include the provision of Covion organic semiconductors as part of their paid customer research licences and “technology packages”. It is also the intention of the parties to discuss and seek to agree on
a case-by-case basis supply agreements for Covion’s commercially available organic semiconductor products. 

  

	9.5	Any confidential information of Covion provided to CDT Limited’s staff involved in the development of Devices along with or after the samples of organic semiconductors referred
to in Clause 9.2 have been provided shall be governed by the provisions of the Materials Evaluation Agreement. Any confidential 

  

 17 

 information of CDT Limited provided pursuant to the collaboration under the Materials Evaluation
Agreement will be governed by the provisions of the Materials Evaluation Agreement. Any Intellectual Property Rights arising out of the collaboration between the staff of CDT Limited involved in the development of Devices and Covion pursuant to the
Materials Evaluation Agreement shall be governed by the Agreement Provisions of the Materials Evaluation Agreement. 
  

	10.	HEALTH AND SAFETY 

  

	10.1	In any case where employees of either party (or any of its Affiliates) visit the premises of the other party (or any of its Affiliates) for the purposes of this Agreement, the first
mentioned party shall: 

  

	 	10.1.1	procure that each such employee complies with all policies, procedures, regulations and rules of the other, party including, without limitation, those applicable to any premises of
the other party to which such employee may have access; and 

  

	 	10.1.2	indemnify the other party against all liabilities, costs, damages and expenses to the extent that the same are caused by any negligent act or omission by any such employee at the
other party’s premises. 

  

	10.2	Whilst carrying out any Project each party (and each of its Affiliates) shall observe and comply with all applicable requirements of the Health and Safety at Work etc. Act 1974 and
any relevant regulations and codes of practice issued thereunder and with all other applicable legal or regulatory requirements. 

  

	11.	TERM AND TERMINATION 

  

	11.1	This Agreement shall come into effect on the Effective Date and, unless terminated earlier in accordance with the following provisions of this clause, shall remain in force for a
period of five years from that date. The Parties shall meet at least six months prior to the expiry of the term of this Agreement to discuss the potential of any future agreement between the parties in relation to the research and development of
organic semiconductors. 

  

	11.2	In the event that either party is in material breach of the terms of this Agreement and, in the case of a breach capable of being remedied, fails to remedy that breach within thirty
days of receiving written notice specifying that breach and requiring the same to be remedied, the other party may terminate this Agreement forthwith by notice in writing. 

  

 18 

	11.3	In the event that: 

  

	 	11.3.1	either party has a liquidator, receiver, administrator or administrative receiver appointed in respect of the whole or any material part of its undertaking or assets or enters into
any arrangement or composition with its creditors or calls a meeting of its creditors or is the subject of an order made or resolution passed for its winding up, whether voluntarily or compulsorily (except for the purposes of a bona fide
reconstruction or amalgamation) or has an event analogous to any of those referred to above happen to it under the laws of any jurisdiction in which it is constituted or registered; and 

  

	 	11.3.2	where such party is Covion whilst such an event referred to in Clause 11.3.1 is continuing (but not after it ceases), Covion fails to pay within fourteen days of demand any sum due
and payable under this Agreement, 

  
 then the
other party may terminate this Agreement forthwith by notice in writing. 
  

	12.	CONSEQUENCES OF TERMINATION 

  

	12.1	Termination of this Agreement shall be without prejudice to the rights of either party which have accrued up to the date of termination and to pursue any remedy in respect of any
breach by the other party of any of the terms of this Agreement including, without limitation, the rights of CDT to sue for and recover any royalties or other payments then due. 

  

	12.2	Upon termination, the Relevant CDT Group Company’s staff shall forthwith cease any activity on any Project, Covion shall lose rights of access to the Device Facilities and the
Relevant CDT Group Company shall hand over to Covion all records of work on the Project, including laboratory notebooks. 

  

	12.3	The provisions of Clauses 4 and 5 of this Agreement relating to the payment of royalties and other sums and the rendering and auditing of accounts and other information shall remain
in force as long as may be necessary in order to wind up the outstanding obligations of both parties hereunder. 

  

	12.4	Upon the termination of this Agreement for any reason the provisions of Clauses 1, 4 and 5 (as provided for in Clause 12.3 above), 6, 7, 9.5, 12, 13 and 16 shall continue in force
in accordance with their respective terms. 

  

	13.	NATURE OF AGREEMENT 

  

	13.1	Each Party acknowledges that in entering into this Agreement it places no reliance on any representation or warranty relating to the subject matter of this Agreement

  

 19 

 save as expressly set out in this Agreement. This Agreement represents the entire agreement between the
parties in relation to the subject matter of this Agreement and supersedes any previous agreement or undertaking between the parties and may not be modified except by an instrument in writing and signed by duly authorised representatives of both
parties. 
  

	13.2	Should any provision of this Agreement, be held to be illegal, invalid or unenforceable in any respect by any judicial or other competent authority under the law of any
jurisdiction: 

  

	 	13.2.1	such provision shall, so far as it is illegal, invalid or unenforceable in any jurisdiction, be given no effect by the parties and shall be deemed not to be included in this
Agreement in that jurisdiction; 

  

	 	13.2.2	the other provisions of this Agreement shall be binding on the parties in that jurisdiction as if such provision were not included herein; 

  

	 	13.2.3	the legality, validity and enforceability of the provision in any other jurisdiction shall not be affected or impaired; and 

  

	 	13.2.4	the parties agree to negotiate in good faith to amend such provision to the extent possible for incorporation herein in such reasonable manner as most closely achieves the intention
of the parties without impairing the parties’ original interests and without rendering such provision invalid or unenforceable. 

  

	13.3	No delay or omission on the part of any party to this Agreement in exercising any right, power or remedy provided by law or under this Agreement shall impair such right, power or
remedy; or operate as a waiver thereof. 

  

	13.4	The single or partial exercise of any right, power or remedy provided by law or under this Agreement shall not preclude any other or further exercise thereof or the exercise of any
other right, power or remedy. 

  

	13.5	The rights, powers and remedies provided in this Agreement are cumulative and not exclusive of any rights, powers and remedies provided by law. 

  

	13.6	Nothing in this Agreement shall be construed so as to constitute either party to be the agent of the other. 

  

	13.7	Nothing in this Agreement and no action taken by the parties pursuant to this Agreement shall constitute a Partnership or joint venture of any kind between the parties hereto.

  

 20 

	13.8	This Agreement shall be binding on the successors and permitted assigns of the parties. 

  

	13.9	Unless expressly provided in this Agreement no term of this Agreement is enforceable pursuant to the Contracts (Rights of Third Parties) Act 1999 by any persons who is not a party
to it. 

  

	13.10	The parties shall make all reasonable endeavours to reach an amicable settlement of any dispute, controversy or difference that may arise between the parties out of or in relation
to this Agreement save as provided in Clause 7.6. In the event of any dispute, controversy or difference that may arise the parties shall in the first instance promptly refer the matter to the parties’ senior business managers. Should the
senior business managers be unable to resolve the dispute within 30 days of the matter being referred to them then the parties shall then promptly refer the matter to a director of each of the parties. Should the directors be unable to resolve the
dispute within 30 days of the matter being referred to them then the matter shall be finally settled, without right of appeal, in accordance with the Rules of Conciliation and Arbitration of the International Chamber of Commerce by an arbitrator or
arbitrators appointed in accordance with said Rules. Such arbitration shall take place in London, England. The provisions of this clause shall not prejudice the application of Clause 11 and shall also not apply to any breach of clauses 6
(Confidentiality) or 7 (Results and Intellectual Property Rights) which, save as provided in Clause 7.6, shall be subject to the non-exclusive jurisdiction of the English courts and for these purposes Covion appoints Avecia Limited as its agent to
accept service and CDT appoints CDT Limited as its agent to accept service. 

  

	13.11	Each party will at all times act in the utmost good faith towards the other in connection with this Agreement and the matters referred to therein. 

  

	13.12	Neither party shall make any announcement with respect to the arrangements contemplated by this Agreement without the written consent of the other as to the form content, and timing
of the announcement (such consent not be unreasonably withheld or delayed). 

  

	13.13	CDT is duly organized, validly existing and in good standing under the laws of Bermuda. This Agreement has been duly executed and delivered by CDT and all obligations of CDT therein
are legal, valid and binding obligations which are enforceable against CDT in accordance with their terms. CDT shall be entitled to perform any of the obligations undertaken by it and to exercise any rights granted to it under this Agreement through
any CDT Group Company. CDT shall ensure and guarantee to Covion that the Relevant CDT Group Company will comply with all obligations in this Agreement as if the Relevant CDT Group Company were party to this Agreement. Any act or omission of the
Relevant CDT Group Company shall be deemed to be the act or omission of CDT pursuant to this Agreement. 

  

 21 

	14.	ASSIGNMENT 

  

	14.1	A party may not assign or transfer all or any part of its rights or obligations under this Agreement without the prior written consent of the other party (such consent not to be
unreasonably withheld or delayed) save that both the benefit and the burden of all its Provisions may be transferred on notice to the other party to the following: 

  

	 	14.1.1	any company which is a subsidiary, fellow subsidiary or holding company of the Party concerned (each a “Qualifying Company”) but, by accepting such a transfer and
as a condition thereof, the transferee shall be deemed to agree with the parties to this Agreement to re-transfer both the benefit and the burden of all its provisions to the party concerned or another of its Qualifying Companies before itself
ceasing to be a Qualifying Company in relation to such Party; or 

  

	 	14.1.2	a purchaser of all or substantially all of the assets of the business to which this Agreement relates, and the parties shall execute such documents as may be appropriate to effect
such assignments. 

  

	14.2	Save as provided by clause 14.1.1, change of control of either party shall have no effect on this Agreement. 

  

	15.	NOTICES 

  

	15.1	All notices and other communications given or made in relation to this Agreement: 

  

	 	15.1.1	shall be in English and in writing, 

  

	 	15.1.2	shall be delivered by hand or sent by express courier (e.g. DHL) or by facsimile; 

  

	 	15.1.3	shall be delivered or sent to the party concerned at the relevant address or facsimile number, shown in clause 15.2 subject to such amendments as may be notified from time to time
in accordance with this clause by the relevant party to the other party by no less than 3 Business Days’ notice; and 

  

 22 

	 	15.1.4	shall be deemed to have been duly given or made if addressed in the aforesaid manner: 

  

	 	(i)	if delivered by hand, upon delivery; 

  

	 	(ii)	if posted by express courier, on the date of receipt; and 

  

	 	(iii)	if sent by facsimile, when a complete and legible copy of the communication has been received at the appropriate address; provided that if any notice or other communication would
otherwise become effective on a non-Business Day or after 5.00 p.m. on a Business Day, it shall instead be deemed to be given or made at 10.00 a.m. on the next Business Day. 

  

	15.2	The initial details for the purposes of clause 15.1 are: 

  

			
	 Covion:
	    	 Covion Organic Semiconductors GmbH
 Industriepark
Hoechst
 Gebaude G864
 D-65926 Frankfurt am Main
 Germany
 Facsimile No.: +49 69 3054 7570
 For the attention of: Managing Director

		
	 With a copy to:
	    	 Avecia Limited
 Legal Affairs Department
 PO Box No. 42, Hexagon House
 Blackley, Manchester
 M9 8ZS
 England
 Facsimile No.: +44 161 721 1886
 For the attention of: Company Secretary

		
	 CDT:
	    	 CDT International Limited
 PO Box HM1556, Comer House
Church
 Parliament Street, Hamilton HMFX
 Bermuda
 Facsimile No.: + 441 292 0961
 For the attention of: James
Whatlington

  

 23 

			
	With a copy to:	  	 Cambridge Display Technology Limited
 Greenwich House,
Madingley Rise
 Madingley Road, Cambridge
 CB3 3 0HJ

England
 Facsimile No.: +44 1223 723503
 For the attention of: Dr D Fyfe

  

	15.3	For the purposes of this clause 15, “Business Day” shall mean any day other than a Saturday, Sunday or Bank or Public Holiday in the United Kingdom or Germany.

  

	16.	GOVERNING LAW AND JURISDICTION 

  
 The construction, validity and performance of this Agreement shall be governed by the laws of England. 
  

	17.	COUNTERPARTS 

  
 This Agreement may be entered into in any number of counterparts and by the parties to it on separate counterparts each of which when executed and delivered shall be an original but all these counterparts shall
together constitute one and the same instrument. 
  

 24 

 IN WITNESS whereof the parties have executed this Agreement on the date first above written. 
  

			
	 Signed for and on behalf of

	 CDT INTERNATIONAL LIMITED

		
	 (Signature)
	 	 /s/ David Fyfe

		
	 (Name)
	 	 David Fyfe

		
	 (Position)
	 	 CEO

		
	 (Date)
	 	 14 December 2001

  

			
	 Signed for and on behalf of

	COVION ORGANIC SEMICONDUCTORS GMBH
		
	 (Signature)
	 	 /s/ Hermann Schenk

		
	 (Name)
	 	 Hermann Schenk

		
	 (Position)
	 	 GESCHÄFTSÜHRER

		
	 (Date)
	 	 14/12/01

  

 25License of Technology, dated January 21, 2002

 Exhibit 10.21 
  
 DATED 21 January 2002 
  
 (1) ISIS INNOVATION LIMITED 
  
 (2) UNIVERSITY OF OXFORD 
  
 (3) UNIVERSITY OF ST ANDREWS 
  
 (4) OPSYS LIMITED 
  
 LICENCE OF TECHNOLOGY 
  
 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH OMISSIONS ARE NOTED BY
“[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION. 

 THIS AGREEMENT dated 21 January 2002 (the “Effective Date”) is made BETWEEN: 

 

	(1)	ISIS INNOVATION LIMITED (Company No. 2199542) whose registered office is at University Offices, Wellington Square, Oxford OX1 2JD, England (“Isis”);

  

	(2)	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD whose administrative offices are at Wellington Square, Oxford OX1 2JD, England (“Oxford”);

  

	(3)	THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS, incorporated by the Universities (Scotland) Act 1899, as amended by the Universities (Scotland) Act 1966 and having its
principal office at College Gate, North Street, St Andrews, Fife, KY16 9AJ (“St. Andrews”); and 

  

	(4)	OPSYS LIMITED (Company No. 3426174) whose registered office is at Unit 8 Begbroke Business & Science Park, Sandy Lane, Yarnton, Kidlington, Oxfordshire 0X5 1PF (the
“Licensee”). 

  
 BACKGROUND: 
  

	(A)	Isis and the Licensee have entered into the following licence agreements (the “Original Licence Agreements”): 

  

									
	 	  	 Agreement Type

	  	 Date

	  	 Title

	  	 Schedule No

	i)	  	Licence	  	20 May 1999	  	Light emitting dendrimers	  	Schedule 1
	ii)	  	Licence	  	17 February 1998	  	Organo-metallic complexes	  	Schedule 2
	ii)	  	Licence	  	17 July 2000	  	Divalent lanthanide metal complexes	  	Schedule 3
	iv)	  	Research: clause 9.2	  	1 December 1998	  	Application of new organo-metallic materials to flat panel displays	  	Schedule 4
	v)	  	Licence	  	25 Jul 2000	  	Improved dendrimers	  	Schedule 5
	vi)	  	Licence	  	6 October 2000	  	Electroluminescent complexes of terbium and dysprosium	  	Schedule 6
	vii)	  	Research: clause 9.2	  	21 December 1999	  	Improving OLPs for light emitting devices	  	Schedule 7
	viii)	  	Research: clause 9.2	  	1 September 1999	  	Lanthanide complexes 1	  	Schedule 8
	ix)	  	Research: clause 9.2	  	1 September 1999	  	Lanthanide complexes 1	  	Schedule 9
	x)	  	Research: clause 9.2	  	1 September 1999	  	Lanthanide complexes 1	  	Schedule 10
	xi)	  	Research: clause 9.2	  	21 December 1999	  	Electroluminescent and transport properties of new phosphor materials	  	Schedule 11

	(B)	Isis and the Licensee now wish to terminate the Original Licence Agreements, in accordance with their terms, and enter into a new Agreement to license the Licensed Technologies (as
defined below). 

  

	(C)	Isis, Oxford and St Andrews (separately or together) may wish to license Licensed Technology to the Licensee in the future, and the Licensee may wish to acquire a Licence to that
Licensed Technology from those parties, and may do so by adding another Schedule to this Agreement in accordance with its terms. 

  
 AGREEMENT: 
  

	1.	TERMINATION OF LICENCE AGREEMENTS 

  
 Isis and the Licensee agree to terminate each of the Original Licence Agreements, according to their terms, as of the Effective Date. 
  

	2.	SUBJECT-MATTER 

  
 This Agreement relates to the technology described in each Schedule appended and to be appended to this Agreement (each a “Licensed
Technology”, collectively the “Licensed Technologies”). 
  

	3.	GRANT 

  
 The licensor described in each Schedule to this Agreement (the “Licensor”) grants to the Licensee licence (the
“Licence”) to license pursuant to clause 5.3 and to use each Licensed Technology in the territory described in each Schedule (the “Territory”) in the production, sale, leasing and other commercial exploitation of
any products and services (the “Licensed Products”, an expression which shall be taken to mean and include only products and services entirely or partially produced by means of or with the use of each Licensed Technology) in the
field described in each Schedule (the “Field”). Licensed Products shall be further defined as: 
  

	 	3.1	any lighting product or device, or display product or device which can be used to display, or otherwise present, digital or analogue data on a screen or viewing surface such
that it is visible or discernible by the human eye as a picture, page of text or other type of representation of the data or signal fed to the device (“Lighting & Display Products”); 

  

 2 

	 	3.2	any chemical compound or polymer or blend of polymers or compounds, doped or co-polymerised, that uses or is composed of any or all of the Licensed Technologies
(“Materials”); and 

  

	 	3.3	any product, device or object which uses any of the Licensed Technologies in any field or for any use which is not otherwise included as a Lighting & Display Product or
Material (“Other Products”). 

  

	4.	UNDERTAKINGS BY THE LICENSOR 

  

	 	4.1	The Licensor will not license other undertakings to exploit a Licensed Technology in the Field. 

  

	 	4.2	Subject to clauses 4.3 and 4.4 (whichever is applicable), the Licensor itself will not exploit a Licensed Technology in the Field. 

  

	 	4.3	Where the Licensor is or includes Oxford and/or St Andrews, the Licensor reserves the right for its employees, students, agents and appointees to use and publish the
Licensor’s Licensed Technology for academic and research purposes (irrespective of fields): and this will include the right for the Licensor to use the Licensor’s Licensed Technologies as enabling technology in other research projects
(including projects which benefit from third-party funding). The Licensor will use reasonable endeavours to submit material intended for publication to the Licensee in writing not less than thirty (30) days in advance of the submission for
publication. The Licensee may request that submission for publication be delayed if such delay is necessary in order to protect the Licensee’s markets for Licensed Products. A delay imposed on submission for publication as a result of a request
made by the Licensee shall not exceed three (3) months from the date of receipt of the material by the Licensee, although the Licensee may ask for additional delay in the rare event that property rights would otherwise be lost. Notification of the
request for delay in submission for publication must be received by the Licensor within thirty (30) days after the receipt of the material by the Licensee, failing which the Licensor shall be free to assume that the Licensee has no objection to the
proposed publication. The material shall be deemed to have been received by the Licensee three (3) days after posting. 

  

	 	4.4	Where the Licensor is or includes Isis, the Licensor reserves the right to grant to Oxford a licence for Oxford and every employee, student, agent and appointee of Oxford, to
use and publish the Licensed Technology for academic and research purposes (irrespective of fields); and this will include the right for Oxford to use the Licensed Technologies as enabling technology in other research projects (including projects
which benefit 

  

 3 

	 	    	from third-party funding). Oxford will use reasonable endeavours to submit material intended for publication to the Licensee in writing not less than thirty (30) days in advance of
the submission for publication. The Licensee may request that submission for publication be delayed if such delay is necessary in order to protect the Licensee’s markets for Licensed Products. A delay imposed on submission for publication as a
result of a request made by the Licensee shall not exceed three (3) months from the date of receipt of the material by the Licensee, although the Licensee may ask for additional delay in the rare event that property rights would otherwise be lost.
Notification of the request for delay in submission for publication must be received by the Licensor within thirty (30) days after the receipt of the material by the Licensee, failing which the Licensor shall be free to assume that the Licensee has
no objection to the proposed publication. The material shall be deemed to have been received by the Licensee three (3) days after posting. 

  

	 	4.5	Nothing in this Agreement shall prevent any registered student of Oxford or St Andrews from submitting for a degree of Oxford or St Andrews a thesis based on the Licensed
Technology, the examination of such a thesis by examiners appointed by Oxford or St Andrews, or the deposit of such a thesis in a library of Oxford or St Andrews in accordance with the relevant procedures of Oxford or St Andrews.

  

	 	4.6	Oxford and St Andrews insofar as they become aware of such information will communicate any improvements to the Licensed Technology which they are obliged to communicate to
the Licensee under any research agreements between Oxford and/or St Andrews and the Licensee which are relevant to the Field. An improvement for this purpose and for the purpose of Clause 5.5 shall be taken to be any development of a Licensed
Technology which, if commercially practised, would infringe and/or be covered by a claim being prosecuted in a patent application included in that Licensed Technology, or by a valid claim of an unexpired patent which issues in response to that
application. 

  

	 	4.7	The Licensor will use its reasonable endeavours not to divulge to third parties such of any know-how or reports marked as confidential communicated by the Licensee pursuant
to this Agreement except that this obligation shall not apply to anything which 

  

	 	4.7.1	is disclosed by any patents or published patent applications; or 

  

	 	4.7.2	is known to the Licensor before the Effective Date, and not impressed already with any obligation of confidentiality to the Licensee; or 

  

 4 

	 	4.7.3	is or becomes publicly known without the fault of the Licensor; or 

  

	 	4.7.4	is obtained by the Licensor from a third party in circumstances where the Licensor has no reason to believe that there has been a breach of an obligation of confidentiality
owed to the Licensee; or 

  

	 	4.7.5	is independently developed by the Licensor; or 

  

	 	4.7.6	is approved for release in writing by an authorised representative of the Licensee; or 

  

	 	4.7.7	the Licensor is specifically required to disclose in order to fulfil an order of any Court of competent jurisdiction. 

  

	5.	UNDERTAKINGS BY THE LICENSEE 

  

	 	5.1	Subject to clause 5.3, the Licensee will use its reasonable endeavours not to divulge to third parties such of the know-how, reports and any other information marked as
confidential communicated by the Licensor pursuant to this Agreement (the “Confidential Technologies”) except that this obligation shall not apply to anything which 

  

	 	5.1.1	is disclosed by any patents or published patent applications included in the Licensed Technologies; or 

  

	 	5.1.2	is known to the Licensee before the Effective Date, and not impressed already with any obligation of confidentiality to the Licensor; or 

  

	 	5.1.3	is or becomes publicly known without the fault of the Licensee; or 

  

	 	5.1.4	is obtained by the Licensee from a third party in circumstances where the Licensee has no reason to believe that there has been a breach of an obligation of confidentiality
owed to the Licensor; or 

  

	 	5.1.5	is independently developed by the Licensee; or 

  

	 	5.1.6	is approved for release in writing by an authorised representative of the Licensor; or 

  

	 	5.1.7	the Licensee is specifically required to disclose in order to fulfil an order of any Court of competent jurisdiction. 

  

	 	5.2	The Licensee will not assign the Licence without the consent of the Licensor, provided that the Licensee may, without the consent of the 

  

 5 

 Licensor, after the second anniversary of the Effective Date, assign this Agreement to a successor in
interest or a transferee of all or substantially all of the portion of the business to which this Agreement relates, after giving the Licensor reasonable prior written notice of such assignment, including a note of the name and address of the
assignee. 
  

	 	5.3	The Licensee may grant sub-licences and may disclose to sub-licensees such of the Confidential Technologies as is necessary for the exercise of the rights sub-licensed. No
sub-licence will carry any right to sub-sub-license without the prior consent of the Licensor which shall not be unreasonably withheld or delayed. Except that the Licensee may grant a sub-licence to Opsys US Corporation that, for so long as Opsys US
Corporation is a wholly owned subsidiary of the Licensee, shall carry the right to grant sub-sub-licences. Immediately following the grant of each sub-licence, the Licensee will forward to the Licensor in writing a note of the name and address of
the sub-licensee, a description of the technology sub-licensed and its intended applications, and confirmation of the duration of the sub-licence. By controlling the wording of its contracts with sub-licensees, the Licensee will ensure that
obligations and conditions matching those recorded in this Agreement, and sufficient to protect the security of the Confidential Technologies, the intellectual property rights in the Licensed Technologies, and the interests of the Licensor, are
imposed on every sub-licensee; and that in no circumstances do the terms of any sub-licence in force from time to time conflict with the terms of this Agreement. 

  

	 	5.4	The Licensee will not exploit the Licensed Technologies after the expiration or termination of this Agreement, insofar as the Licensed Technologies are still patented or
secret: provided that this sub-clause shall not prevent the Licensee from working an expired patent which can be worked by all other manufacturers. 

  

	 	5.5	The Licensee will communicate to the Licensor in writing all improvements which the Licensee makes to a Licensed Technology in the Field, and all new applications of a
Licensed Technology which the Licensee devises. The Licensee grants the Licensor a non-exclusive royalty free licence to use all such improvements for academic and research purposes only, with the right to sub-license (where necessary) Oxford and/or
St Andrews and every employee, student, agent and appointee of Oxford and/or St Andrews to use and publish all such improvements for academic and research purposes only. The Licensor will use reasonable endeavours to submit material intended for
publication to the Licensee in writing not less than thirty (30) days in advance of the 

  

 6 

 submission for publication. The Licensee may request that submission for publication be delayed if such
delay is necessary in order to protect the Licensee’s markets for Licensed Products. A delay imposed on submission for publication as a result of a request made by the Licensee shall not exceed three (3) months from the date of receipt of the
material by the Licensee, although the Licensee may ask for additional delay in the rare event that property rights would otherwise be lost. Notification of the request for delay in submission for publication must be received by the Licensor within
thirty (30) days after the receipt of the material by the Licensee, failing which the Licensor shall be free to assume that the Licensee has no objection to the proposed publication. The material shall be deemed to have been received by the Licensee
three (3) days after posting. 
  

	 	5.6	The Licensee will inform the Licensor of any misappropriation or infringement of the Licensed Technologies of which the Licensee becomes aware; and whenever it is not the
case that the Licensee takes legal action against such misappropriation or infringement pursuant to clauses 5.10 and 5.11, the Licensee will on request assist the Licensor in taking such action. 

  

	 	5.7	In the event of any of the Confidential Technologies becoming publicly known other than by action or omission of the Licensor, the Licensee will continue paying royalties
under clause 6, until the end of this Agreement, without prejudice to the payment of any additional damages in the event of any of the Confidential Technologies becoming publicly known as a result of breach of this Agreement.

  

	 	5.8	The Licensee will be responsible for the design and construction of the Licensed Products and the Licensor shall have no responsibility or liability in that respect.

  

	 	5.9	The Licensee will ensure that the Licensed Products and the packages associated with them are marked suitably with any relevant patent or patent application numbers to
satisfy the laws of each of the countries in which the Licensed Products are sold or supplied and in which they are covered by the claims of any patent or patent application. 

  

	 	5.10	The Licensee shall, at its own cost and expense, apply for, renew and defend such patent, design, copyright and other registrations as the Licensor and the Licensee agree is
reasonably necessary for the protection of the Licensed Technologies. However, the Licensee must: 

  

	 	5.10.1	use a patent agent approved by the Licensor to assist it in so doing; 

  

 7 

	 	5.10.2	not take any official actions arising from examination proceedings in relation to any patent applications included in the Licensed Technologies without obtaining the prior
written consent of the Licensor (such consent not to be unreasonably withheld or delayed); and 

  

	 	5.10.3	instruct the patent agent selected in accordance with clause 5.10.1 to promptly forward to each Licensor (in confidence and for its information only) copies of all
correspondence generated by the patent agent in respect of the Licensed Technologies. 

  

	 	5.11	If the Licensor believes a patent may be granted in a country but the Licensee is unwilling to prosecute the application there, the country in question shall be removed from
the scope of this Agreement provided the Licensor files in that country. In the event of the Licensor making such a filing the Licensee shall have the right to reconsider its position, and the country will be reinstated provided the Licensee agrees
to pay all historic and future patent costs. The Licensee shall have thirty (30) days to reconsider after being informed of such a filing. 

  

	 	5.12	Before abandoning or materially reducing the scope of any patent application included in the Licensed Technologies (other than an application which is replaced by another
application claiming the same priority in the same country as the first mentioned application) or before withholding payment of any fee necessary for procuring or keeping in force any patent to which this Agreement applies, the Licensee shall give
to the Licensor adequate notice of its intended course of action (at least 28 days), so as to enable the Licensor to discuss such course of action with the Licensee. If no agreement is reached then the Licensor shall itself be entitled to prosecute
such patent application at its own cost, such patent application shall be removed from the scope of this Agreement and the Licensee shall have no liability to the Licensor in relation to the same. 

  

	 	5.13	Prior to taking legal action against any misappropriation or infringements of the Licensed Technologies in accordance with clause 5.10, the Licensee must:

  

	 	5.13.1	provide the Licensor with an indemnity in terms satisfactory to the Licensor against all costs (including lawyers’ and patent agents’ fees and expenses) claims,
demands and liabilities arising out of or consequent upon such activities; and 

  

	 	5.13.2	agree with the Licensor the terms on which any damages or other recovery are to be shared with the Licensor. 

  

 8 

	6.	ROYALTIES 

  

	 	6.1	The Licensee agrees to pay to the Licensor, the signing fee for each Licensed Technology set out in each Schedule to this Agreement (the “Signing Fee”) on
the date specified in each Schedule (“Signing Fee Date”). 

  

	 	6.2	For so long as any Licensed Products are used or marketed by the Licensee, the Licensee will pay to the Licensor, in respect of each Licensed Technology, a royalty, equal to
the royalty rate set out in clauses 6.2.1, 6.2.2 and 6.2.3 (the “Royalty Rate”), on the gross selling price of all Licensed Products in the form in which they are sold, leased or licensed to a customer by the Licensee (recorded as
required and appropriate pursuant to this Agreement in the standard customer pricing records of the Licensee if and to the extent that such records are applicable to the Licensed Product in question and provided that such records shall be true and
verifiable by independent auditors according to standard and accepted accounting practice). 

  

	 	6.2.1	For Lighting & Display Products the Royalty Rate shall be [**] of the gross selling price for each patent or patent application licensed under this Agreement
(“Licensed Patent”) employed in a Lighting & Display Product up to a maximum of [**] of the gross selling price; 

  

	 	6.2.2	For Materials the Royalty Rate shall be [**] of the gross selling price for each Material; and 

  

	 	6.2.3	For Other Products the parties involved shall negotiate an agreed Royalty Rate when such Other Product is first put on the market. 

  

	 	6.3	For so long as the Licensee sub-licenses the Licensed Technologies, the Licensee will pay to the Licensor, in respect of each licensed Technology, a royalty, equal to the
sub-licensing royalty rate set out in clauses 6.3.1, 6.3.2 and 6.3.3 (the “Sub-Licensing Royalty Rate”) on the total gross receipts received by the Licensee from a sub-licensee in respect of each Licensed Technology.

  

	 	6.3.1	For Lighting & Display Products [**] of the gross receipts; 

  

	 	6.3.2	For Materials [**] of the gross receipts, and 

  

 9 

	 	6.3.3	For Other Products the parties involved shall negotiate an agreed Sub-Licensing Royalty Rate when such Other Product is first put on the market. 

  

	 	6.4	In the event that the total of all the royalties paid to the Licensor under Clauses 6.2 and 6.3, in respect of all the Licensed Technologies, does not aggregate in each
applicable Licence Year (as defined below) to the total of all the minimum sums, Individually, described in each Schedule to this Agreement (the “Minimum Sums”), the Licensee will make up the difference between the total royalties
paid in respect of the Licensed Technologies and the total of all the Minimum Sums. 

  

	 	6.5	The Licensee shall provide each Licensor with a royalty report within sixty (60) days of each anniversary of the Effective Date of this Agreement (the “Licence
Year”) for each Licensed Product marketed, and for each Licensed Product brought into use by or within the groups of the Licensee. Each report shall state the gross selling prices, the gross receipts received from sub-licensees, identify
the applicable Licensed Technology by Schedule number and provide a calculation of the royalties due. 

  

	 	6.6	Within a reasonable time of receipt of a royalty report referred to in clause 6.5, the licensor nominated in each Schedule to this Agreement (the “Nominated
Licensor”) will invoice the Licensee for the royalties due in respect of each Licensed Technology and the Licensee will pay such invoice in full satisfaction of royalties due to the Licensor under this clause within 30 days of receipt.

  

	 	6.7	In marketing the Licensed Products, the Licensee will not accept or solicit any non-monetary consideration without the prior written consent of the Licensor. The use by the
Licensee of a commercially reasonable quantity of Licensed Products for promotional sampling shall not violate this prohibition. 

  

	 	6.8	In the case of a Licensed Product which is not marketed, but rather manufactured by the Licensee for use by that party, or within that party’s group, the term
“gross selling price” shall mean [**] of the gross selling price of the Licensed Product in the form in which it is so used, as recorded in the standard customer pricing records of the Licensee if and to the extent that such records are
applicable to the Licensed Product in question, or as ascertained by applying reasonable uplifts to the standard, fully-absorbed cost of the Product to the Licensee if and to the extent that those records are not so applicable. For the avoidance of
doubt, this clause shall not apply to Licensed Product used by the Licensee or within the Licensee’s group solely for the purposes of internal research or solely for the purposes of internal quality control. 

  

 10 

	 	6.9	For the purpose of calculating royalties under this clause 6, a Licensed Product shall be regarded as sold, leased or licensed by the Licensee or a sub-licensee of the
Licensee which is a wholly owned subsidiary of the Licensee, when invoiced, or if not invoiced, when shipped or despatched by the Licensee. If a Licensed Product is marketed by a sub-licensee of the Licensee which is a wholly owned subsidiary of the
Licensee, the royalty on each such Licensed Product shall be calculated under clause 6.2. 

  

	 	6.10	If the Licensee is obliged to pay royalties in respect of a Licensed Product to a third party (other than the Licensee’s parent, subsidiary, associated or affiliated
companies) for the right to make, use or sell a Licensed Product, then the Licensee shall be entitled to deduct from the royalty payment due to the Licensor in respect of that Licensed Technology the royalty payment actually made to such third
party, up to a maximum of [**] or the royalty payment due to the Licensor in respect of that Licensed Technology. 

  

	 	6.11	All payments provided for under this clause 6 shall be made to the Licensor in pounds sterling without any deductions apart from any tax which is required to be withheld
under applicable local law. Any change of currency made to calculate sales for the purpose of this clause 6 shall be determined as at the last business day of each quarter, using the average dally buying and selling rates quoted by Barclays Bank plc
on that day. Where the Licensee is required to withhold tax under applicable local law, the Licensee shall deduct such tax, pay it to the relevant taxing authority, and supply the Licensor with a Certificate of Tax Deduction at the time of payment
to the Licensor. The parties shall co-operate under any applicable Double Taxation Treaty so that, if possible, payments are made gross or, if payment gross is not possible, the Licensor obtains appropriate relief under the Treaty.

  

	 	6.12	Where the Licensee is obliged to make a payment to the Licensor under this Agreement which attracts value-added, sales, use, excise or other similar taxes or duties, the
Licensee shall be responsible for paying such taxes and duties. 

  

	 	6.13	In the event that full payment of any amount due from the Licensee to the Licensor under this Agreement is not made by any of the dates stipulated, the Licensee shall be
liable to pay interest on the amount unpaid at the rate of four per cent (4%) per annum over the base rate for the time being of Barclays Bank plc, from the date when payment was due until the date of actual payment. 

  

 11 

	 	6.14	The Licensee shall keep complete and accurate accounts of all Licensed Products used and marketed and all Licensed Technologies sub-licensed to third parties; and will permit
the Licensor or its agents to audit such accounts once per year solely for the purpose of determining the accuracy of the royalty reports and payments no more than once per Licence Year. The Licensee’s obligation concerning audit of its
accounts shall terminate as to any report six (6) years after the date of that report. 

  

	7.	DURATION AND TERMINATION 

  

	 	7.1	This Agreement shall take effect on the Effective Date and (subject to the remaining sub-clauses of this clause 7) shall continue in force in respect of each Licensed
Technology until the expiration of the period of ten (10) years from the date on which a Licensed Product is first put on the market by the Licensee or one of its sub-licensees. 

  

	 	7.2	Insofar as the rights and obligations in this Agreement concern Territories in which the commercial practice of a Licensed Technology is covered by a claim being prosecuted
in a patent application included in that Licensed Technology, or by a valid claim of an unexpired patent which issues in response to that application, those rights and obligations shall extend in respect of that particular Licensed Technology for
those Territories beyond the period defined in clause 7.1 if and for so long as the commercial practice of that Licensed Technology is so covered in those territories. 

  

	 	7.3	If any party commits a material breach of this Agreement, and the breach is not remedied (where remediable) within the period allowed by notice given by any of the other
parties in writing calling on the party in breach to effect such remedy (such period being not less than thirty (30) days), any of the parties may by further written notice terminate this Agreement immediately. 

  

	 	7.4	The Licensee will use its reasonable endeavours to protect, develop and exploit the Licensed Technologies. Within sixty (60) days after the end of each Licence Year, the
Licensee shall provide the Licensor with a report detailing the progress made and steps taken during the Licence Year for each Licensed Technology in: 

  

 12 

	 	7.4.1	applying for and defending any patent, design, trade mark, copyright, mask work and other registrations which may be available for the protection of the Licensed Technology;

  

	 	7.4.2	taking legal action against any misappropriation or infringement of the Licensed Technologies of which the Licensee becomes or is made aware; 

  

	 	7.4.3	developing the Licensed Technologies in order to facilitate its commercial exploitation; and 

  

	 	7.4.4	promoting and marketing Licensed Products. 

  

	 	    	Any failure by the Licensee to provide the Licensor with such a report during the sixty-(60)-day period shall be regarded as a material breach of the provisions of this Agreement,
for the purpose of clause 7.3. Furthermore, if the Licensor, on reasonable and demonstrable grounds, concludes from any such report that the progress made and steps taken by the Licensee are insufficient or inadequate, the Licensed Technology in
relation to which the Licensee has taken insufficient or inadequate steps will be removed from the scope of this Agreement. 

  

	 	7.5	The Licensee may terminate this Agreement by six (6) months’ written notice at any time; whereupon the Licensee shall bring all sub-licences to an end on the same date.
Any such termination shall not absolve the Licensee of its obligation to accrue and pay royalties under the provisions of clause 6 of this Agreement. 

  

	 	7.6	The Licensor shall have the right to terminate this Agreement by serving written notice on the Licensee in the event that the Licensee has a petition presented for its
winding-up, or passes a resolution for voluntary winding-up otherwise than for the purposes of a bona fide amalgamation or reconstruction, or compounds with its creditors, or has a receiver or administrative receiver appointed of all or any part of
its assets, or enters into any arrangements with creditors, or takes or suffers any similar action in consequence of debts. Such notice may terminate this Agreement either immediately or at the end of such period as the Licensor shall select.

  

	 	7.7	If the Licensee contests the secret or substantial nature of the Confidential Technology, or challenges the validity of any patent contained within the Licensed Technology,
or raises the claim that such a patent is not necessary, the Licensed Technology challenged by the Licensee will be removed from the scope of this Agreement and the Licensee will have no further rights in that technology. 

 

 13 

	 	7.8	The Licensor shall have the right by serving written notice on the Licensee to require the Licensee to prove that the Licensed Technology is not being licensed or used by the
Licensee for the production of products or the provision of services other than those licensed provided that in such notice the Licensor sets out in reasonable detail the reasons why it has cause to believe that the Licensee is so using the Licensed
Technology. 

  

	 	7.9	Clauses 4.7, 5.1, 5.4, 5.5 (in respect of only the licence of improvements made prior to termination or expiration of this agreement), 5.5 (in respect only of the obligation
to assist the Licensor in taking such legal action at the Licensor’s expense), 7.9, 8, 9, 10 and 11.6 shall survive the termination or expiration of this Agreement, for whatever reason. 

  

	8.	LIABILITY 

  

	 	8.1	The Licensee agrees to indemnify the Licensor and hold the Licensor harmless from and against any and all claims, damages and liabilities asserted by third parties (including
claims for negligence) which arise directly or indirectly from the use of the Licensed Technologies or the sale of Licensed Products by the Licensee and its sub-licensees. 

  

	 	8.2	The Licensor makes no representation or warranty that advice given to the Licensee pursuant to this Agreement by any employee, student, agent or appointee of the Licensor, or
the use of any works, designs or information which they or the Licensor provide in connection with this Agreement, will not result in infringement of third-party rights. 

  

	 	8.3	The Licensee undertakes to make no claim against any employee, student, agent or appointee of the Licensor, being a claim which seeks to enforce against any of them any
liability whatsoever in connection with this Agreement or its subject-matter. 

  

	 	8.4	The liability of any party for any breach of this Agreement, or arising in any other way out of the subject-matter of this Agreement, will not extend to any incidental or
consequential damages or losses or to any loss of profits. 

  

	 	8.5	In any event, the maximum liability of the Licensor to the Licensee under or otherwise in connection with this Agreement or its subject-matter shall not exceed the return of
all royalties paid by the Licensee to the Licensor under this Agreement, together with interest on the balance of such moneys from time to time outstanding, accruing from day to day at the rate of four percent (4%) per annum over the Barclays Bank
plc base rate from time to time in force and compounded annually as at 31 December. 

  

 14 

	 	8.6	If any sub-clause of this clause 8 is held to be invalid or unenforceable under any applicable statute or rule of law, then it shall be deemed to be omitted, and if as a
result any party becomes liable for loss or damage which would otherwise have been excluded, then such liability shall be subject to the remaining sub-clauses of this clause 8. 

  

	9.	FORCE MAJEURE 

  
 If the performance by either party of any of its obligations under this Agreement (other than an obligation to make payment) shall be prevented by
circumstances beyond its reasonable control, then such party shall be excused from performance of that obligation for the duration of the relevant event. 
  

	10.	NOTICES 

  
 Isis’ representative for the purpose of receiving payments and notices shall until further notice be: 
  
 The Managing Director 
 Isis Innovation Limited 
 Ewert House, Ewert
Place 
 Summertown 
 OXFORD OX2
7SG 
  
 Oxford’s representative for the purpose of receiving
payments and notices shall until further notice be: 
  
 The
Director of Research Services 
 University of Oxford 
 Wellington Square 
 OXFORD OX1 2JD 
  
 St Andrews’ representative for the purpose of receiving notices shall until further notice be: 
  
 The Director or Research and Enterprise Services 
 University of St Andrews 
 St Andrews

 Fife KY16 9AJ 
  

 15 

 The Licensee’s representative for the purpose of receiving notices shall until further notice be:

  
 The Chief Executive Officer 
 Opsys Limited 
 Unit 8 
 Begbroke Business & Science Park 
 Sandy
Lane, Yarnton 
 Kidlington, OX5 1PF 
  

	11.	GENERAL 

  

	 	11.1	Clause headings are inserted in this Agreement for convenience only, and they shall not be taken into account in the interpretation of this Agreement.

  

	 	11.2	Nothing in this Agreement shall create, imply or evidence any partnership or joint venture between the Licensor and the Licensee or the relationship between them of principal
and agent. 

  

	 	11.3	This Agreement constitutes the entire agreement between the parties with regard to the Licence and all previous agreements with respect to the Licensed Technologies are
hereby terminated according to their terms. 

  

	 	11.4	This Agreement does not impose or imply any obligation on the Licensor to conduct development work; any arrangements for such work shall be the subject of a separate
agreement between the Licensor and the Licensee. 

  

	 	11.5	If the parties wish to include a new Licensed Technology within the scope of this Agreement, they may only do so by adding a new Schedule to this Agreement in the form of the
Sample Schedule (“Sample Schedule”) in the Appendix. For the avoidance of doubt, there is no obligation on either of the parties to add a new Schedule to this Agreement. Any variation of this Agreement, including the addition of a
new Licensed Technology by way of a new Schedule to this Agreement, shall be in writing and signed by authorised signatories for all parties. 

  

	 	11.6	This Agreement shall be governed by English Law, and the parties submit to the exclusive jurisdiction of the English Courts for the resolution of any dispute which may arise
out of this Agreement. 

  

	 	11.7	If any one or more clauses or sub-clauses of this Agreement would result in this Agreement being prohibited pursuant to any competition law, then it or they shall be deemed
to be omitted. The parties shall uphold the remainder of this Agreement, and shall negotiate an amendment which, as far as legally feasible, maintains the economic balance between the parties. 

  

 16 

	 	11.8	The parties to this Agreement intend that by virtue of the Contracts (Rights of Third Parties) Act 1999 the people referred to in clause 8.3 will be able to enforce the terms
of this Agreement as if the people referred to in clause 8.3 were a party to it. 

  

 17 

 APPENDIX 
  

SAMPLE SCHEDULE 
  
 Licensed Technology (clause 1): 
  

	(a)	the invention (the “Invention”) described in International Patent Application No.
PCT/GB<            >, which was filed on <                    >
with the priority date <                    > and entitled
<                    > (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the Inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential Information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  
 Isis Reference (if applicable): 
  
 Applicable Research Contract: 
  
 Licensor (clause 3): 
  
 Territory (clause 3): 
  
 Field (clause
3): 
  
 Signing Fee (clause 6.1): 
  
 Signing Fee Date (clause 6.1): 
  

					
	 Minimum Sum (clause 6.4):
  
	 	 Licence Year

	 	 Minimum Sum

 Nominated Licensor (clause 6.6): 
  

			
	 SIGNED for and on behalf of
 OPSYS LIMITED:
	 	 
		
	Name:	 	 
	Position:	 	 
	Signature:	 	 
		
	 SIGNED for and on behalf of
 LICENSOR A:
	 	 SIGNED for and on behalf of
 LICENSOR B:

		
	Name:	 	Name:
	Position:	 	Position:
	Signature:	 	Signature:

  

			
	SCHEDULE 1	 	Effective date:     20 May 1999

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in International Patent Application No. PCT/GB98/03172 which was filed on 23 October 1998, with priority date 23 October
1997 and entitled Light Emitting Dendrimers (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/0053
		
	Applicable Research Contract:	 	Not applicable
		
	Licensor (clause 3):	 	ISIS Innovation Ltd. (with University of Durham, which is not a Licensor)
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3);	 	Any and all applications.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 2	 	Effective date     17 February 1998

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in International Patent Application No. PCT/GB98/01587, which was filed on 1 June 1998, with priority date 2 June 1997 and
entitled Organometallic Complexes (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the Inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/0166
		
	Applicable Research Contract:	 	Royal Society Fellowship (Dr V Christou)
		
	Licensor (clause 3):	 	ISIS Innovation Ltd.
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Light emitter technology and devices based upon organolanthanide and other photonic materials.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 3	 	Effective date     17 July 2000

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in International Patent Application No. PCT/GB99/03201, which was filed on 24 September 1999, with priority date 25
September 1998 and entitled Divalent Lanthanide Metal Complexes (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/0599
		
	Applicable Research Contract:	 	 CASE Award (C Shipley) Royal Society Fellowship
 (V
Christou)

		
	Licensor (clause 3):	 	ISIS Innovation Ltd.
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Data (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 4	 	Effective date     18 June 1999

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in International Patent Application No. PCT/GB00/02377 which was filed on 19 June 2000, with priority date 18 June 1999
and entitled Flat Panel Display with Improved Contrast (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the Inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/0696
		
	Applicable Research Contract:	 	“Application of new organometallic materials to flat panel displays”, Opsys, dated 1 December 1998.
		
	Licensor (clause 3):	 	ISIS Innovation Ltd.
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Light emitter technology and devices based upon organolanthanide and other photonic materials.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 5	 	Effective date     25 July 2000

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in International Patent Application No. PCT/GB01/00522, which was flied on 9 February 2001, with Priority Date 9 February
2000 and entitled Improved Dendrimers (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/806
		
	Applicable Research Contract:	 	“Lanthanide complexes 2” dated 1 September 1999, but renamed “Electroluminescent materials” and extended, dated 6 September 2000.
		
	Licensor (clause 3):	 	ISIS Innovation Ltd.
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 6	 	Effective date     6 October 2000

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in United Kingdom Patent Application No. GB0022081.4 which was filed on 8 September 2000 and entitled Pyrazolone
Lanthanide Complexes (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the Inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/862
		
	Applicable Research Contract:	 	 CASE Award (M Etchells) Royal Society Fellowship
 (V
Christou)

		
	Licensor (clause 3):	 	ISIS Innovation Ltd.
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 7	 	Effective date:     26 February 2001

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in United Kingdom Patent Application No. GB0104700.0, which was filed on 26 February 2001 and entitled Luminescent
Polymers (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/928
		
	Applicable Research Contract:	 	“Improving OLPs for light emitting devices”, RSO reference DH371
		
	Licensor (clause 3):	 	ISIS Innovation Ltd.
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Light emitter technology and devices based upon organolanthanide and other photonic materials.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd

			
	SCHEDULE 8	 	Effective date:     20 February 2001

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in United Kingdom Patent Application No. GB0104176.3 which was filed on 20 February 2001 and entitled Asymmetric
Dendrimers (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/940
		
	Applicable Research Contract:	 	“Lanthanide Complexes 1”, RSO reference DM280.
		
	Licensor (clause 3):	 	ISIS Innovation Ltd., University of St. Andrews
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 9	 	Effective date:     20 February 2001

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in United Kingdom Patent Application No. GB0104175.5 which was filed on 20 February 2001 and entitled Metal Containing
Dendrimers (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Cause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/941
		
	Applicable Research Contract:	 	“Lanthanide Complexes 1”, RSO reference DM280.
		
	Licensor (clause 3):	 	ISIS Innovation Ltd., University of St. Andrews
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 10	 	Effective date:     20 February 2001

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described In United Kingdom Patent Application No. GB0104177.1 which was filed on 20 February 2001 and entitled Aryl Aryl Dendrimers
(the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/997
		
	Applicable Research Contract:	 	“Lanthanide Complexes 1”, RSO reference DM280.
		
	Licensor (clause 3):	 	ISIS Innovation Ltd., University of St. Andrews
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 11	 	Effective date:     28 August 2001

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in United Kingdom Patent Application No. GB0120828.9 which was filed on 28 August 2001 and entitled Method of Driving an
Electroluminescent Display (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential Information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/1054
		
	Applicable Research Contract:	 	“Study of the electroluminescent and transport properties of the new phosphor materials”, RSO ref DJ565.
		
	Licensor (clause 3):	 	ISIS Innovation Ltd.
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Light emitter technology and devices based upon organolanthanide and other photonic materials.
		
	Signing Fee (clause 6.1):	 	Not applicable
		
	Signing Fee Date (clause 6.1):	 	Not applicable
		
	Minimum Sum (clause 6.4):	 	Not applicable
		
	Nominated Licensor (clause 6.6):	 	ISIS Innovation Ltd.

			
	SCHEDULE 12	 	DRAFT
		
	 	 	Effective Date:

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in British Patent Application No. GB0206169.5, which was filed on 15th March, 2002 and entitled “Rhenium
Compounds” (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/1171
		
	Applicable Research Contract:	 	Improving OLP’s for Light Emitting Devices (University Account Ref: HDHHX); Clause 9.2 as amended by Opsys Letter of 16th March, 2001.
		
	Licensor (clause 3):	 	Isis Innovation Limited
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications
		
	Nominated Licensor (clause 6.1):	 	N/A
		
	Signing Fee (clause 6.1):	 	None
		
	Signing Fee Date (clause 6.1):	 	N/A
		
	Royalty Rate (clause 6.2):	 	As specified.
		
	Sub-licensing Royalty Rate (clause 6.3):	 	As specified
		
	Minimum Sum (clause 6.4):	 	N/A

			
	SCHEDULE 12	 	DRAFT
		
	 Signed for and on behalf of CDT Oxford
 Limited:
	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
		
	 Signed for and on behalf of Isis Innovation
 Limited:
	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 

			
	SCHEDULE 13	 	DRAFT
		
	 	 	Effective Date:

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in British Patent Application Nos. GB0206356.8, which was filed on 18th March, 2002, and GB0220091.3, which was filed on
29th August, 2002, both entitled “Phosporescent Dendrimers” (the “Applications”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the Inventors named in the above Applications (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA1200-1 and 1200-2
		
	 Applicable Research
 Contract:
	 	 Oxford: Information to be inserted.
 St. Andrews:
Schedule 5 of “Framework Agreement for the Sponsorship of a Research Programme” Ref: XIUO02.

		
	Licensor (clause 3):	 	Isis Innovation Limited and the University of St. Andrews.
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications
		
	Nominated Licensor (clause 6.1):	 	Isis Innovation Limited
		
	Signing Fee (clause 6.1):	 	None
		
	Signing Fee Date (clause 6.1):	 	NIA
		
	Royalty Rate (clause 6.2):	 	As specified
		
	Sub-licensing Royalty Rate (clause 6.3):	 	As specified
		
	Minimum Sum (clause 6.4):	 	N/A

			
	SCHEDULE 13	 	DRAFT
		
	 Signed for and on behalf of CDT Oxford
 Limited:
	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
	
	Signed for and on behalf of the Nominated Licensor (Isis Innovation Limited):
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
		
	Signed for and on behalf of the University of St. Andrews:	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 

			
	SCHEDULE 14	 	DRAFT
		
	 	 	Effective Date:

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in British Patent Application No. GB0220080.6, which was filed on 29th August, 2002 and entitled “Blended
Dendrimers” (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential Information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/1276
		
	 Applicable Research
 Contract:
	 	 Oxford: Information to be inserted.
 St. Andrews:
Schedule 5 to “Framework Agreement for the Sponsorship of a Research Programme” Ref: XIUO02

		
	Licensor (clause 3):	 	Isis Innovation Limited and the University of St. Andrews
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications
		
	Nominated Licensor (clause 6.1):	 	Isis Innovation Limited
		
	Signing Fee (clause 6.1):	 	None
		
	Signing Fee Date (clause 6.1):	 	N/A
		
	Royalty Rate (clause 6.2):	 	As specified
		
	Sub-licensing Royalty Rate (clause 6.3):	 	As specified
		
	Minimum Sum (clause 6.4):	 	N/A

			
	SCHEDULE 14	 	DRAFT
		
	 Signed for and on behalf of CDT Oxford
 Limited:
	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
	
	Signed for and on behalf of the Nominated Licensor (Isis Innovation Limited):
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
		
	Signed for and on behalf of the University of St. Andrews:	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 

			
	SCHEDULE 15	 	DRAFT
		
	 	 	Effective Date:

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in British Patent Application No. GB0219987.5, which was filed on 28th August, 2002 and entitled “Intramolecular interactions in organometallics” (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/1277
		
	 Applicable Research
 Contract:
	 	 Oxford: Information to be inserted.
 St. Andrews:
Schedule 5 to “Framework Agreement for the Sponsorship of a Research Programme” Ref: XIUO02

		
	Licensor (clause 3):	 	Isis Innovation and the University of St. Andrews
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications
		
	Nominated Licensor (clause 6.1):	 	Isis Innovation Limited
		
	Signing Fee (clause 6.1):	 	None
		
	Signing Fee Date (clause 6.1):	 	N/A
		
	Royalty Rate (clause 6.2):	 	As specified
		
	Sub-licensing Royalty Rate (clause 6.3):	 	As specified
		
	Minimum Sum (clause 6.4):	 	N/A

			
	SCHEDULE 15	 	DRAFT
		
	 Signed for and on behalf of CDT Oxford
 Limited:
	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
	
	Signed for and on behalf of the Nominated Licensor (Isis Innovation Limited):
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
		
	Signed for and on behalf of the University of St. Andrews:	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 

			
	SCHEDULE 16	 	DRAFT
		
	 	 	Effective Date:

  
 Licensed Technology (clause 1):

  

	(a)	the invention (the “Invention”) described in British Patent Application No. GB0222268.5, which was filed on 25th September, 2002 and entitled “Fluorene Containing Dendrimers” (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement 

  

			
	Isis Reference:	 	RJA/1278
		
	 Applicable Research
 Contract:
	 	 Oxford: Information to be inserted.
 St. Andrews:
Schedule 5 to “Framework Agreement for the Sponsorship of a Research Agreement” Ref: XIUO02.

		
	Licensor (clause 3):	 	Isis Innovation Limited and the University of St. Andrews.
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications
		
	Nominated Licensor (clause 6.1):	 	Isis Innovation Limited
		
	Signing Fee (clause 6.1):	 	None
		
	Signing Fee Date (clause 6.1):	 	N/A
		
	Royalty Rate (clause 6.2):	 	As specified
		
	Sub-licensing Royalty Rate (clause 6.3):	 	As specified
		
	Minimum Sum (clause 6.4):	 	N/A

			
	SCHEDULE 16	 	DRAFT
		
	 Signed for and on behalf of CDT Oxford
 Limited:
	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
	
	Signed for and on behalf of the Nominated Licensor (Isis Innovation Limited):
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
		
	Signed for and on behalf of the University of St. Andrews:	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 

			
	SCHEDULE 17	 	DRAFT
		
	 	 	Effective Date:

  
 Licensed Technology (clause 1):

  

	(a)	the Invention (the “Invention”) described in British Patent Application No. GB0220092.1, which was flied on 29th August, 2002 and entitled “Reactive Dendrimers” (the “Application”); 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and 

  

	(d)	technology so communicated to the Licensee pursuant to Clause 4.6 of this Agreement. 

  

			
	Isis Reference:	 	RJA/1279
		
	 Applicable Research
 Contract:
	 	 Oxford: Information to be inserted.
 St. Andrews:
Schedule 5 to Framework Agreement for the Sponsorship of a Research Agreement” Ref: XIUO02

		
	Licensor (clause 3):	 	Isis Innovation Limited and the University of St. Andrews
		
	Territory (clause 3):	 	Worldwide
		
	Field (clause 3):	 	Any and all applications
		
	Nominated Licensor (clause 6.1):	 	Isis Innovation Limited
		
	Signing Fee (clause 6.1):	 	None
		
	Signing Fee Date (clause 6.1):	 	N/A
		
	Royalty Rate (clause 6.2):	 	As specified
		
	Sub-licensing Royalty Rate (clause 6.3):	 	As specified
		
	Minimum Sum (clause 6.4):	 	N/A

			
	SCHEDULE 17	 	DRAFT
		
	 Signed for and on behalf of CDT Oxford
 Limited:
	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
	
	Signed for and on behalf of the Nominated Licensor (Isis Innovation Limited):
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 
		
	Signed for and on behalf of the University of St. Andrews:	 	 
		
	Name:	 	 
		
	Position:	 	 
		
	Signature:	 	 

 AS WITNESS the hands of authorised signatories for the parties on the date first mentioned above 
  
 SIGNED for and on behalf of 
 ISIS INNOVATION LIMITED: 
  
 Name: Mr T Hockaday 
  
 Position:
Director of Special Projects Isis Innovation, Ltd 
  
 Signature: /s/ Mr T
Hockaday 
  
 SIGNED for and on behalf of 
 THE CHANCELLOR, MASTERS 
 AND SCHOLARS OF THE 
 UNIVERSITY OF OXFORD: 
  
 Name: R. Lewicki 
  
 Position: Head
of Contracts 
  
 Signature: /s/ R. Lewicki 
  
 SIGNED for and on behalf of 
 THE UNIVERSITY OF ST ANDREWS: 
  
 Name: Julie Clark 
  
 Position: Associate Director 
  
 Signature: /s/ Julie Clark 
  
 SIGNED for and on behalf of
 
 OPSYS LIMITED: 
  
 Name: Michael Holmes 
  
 Position: CEO 
  
 Signature: /s/
Michael Holmes 
  

 18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]